EXPERIENCE WITH THE USE OF HIGH-FLOW NASAL CANNULAS IN ADULT PATIENTS WITH COVID-19, HOSPITAL UNIVERSITARIO SAN IGNACIO – BOGOTÁ, D.C. 2020 TO 2022
Experiencia con el uso de cánulas nasales de alto flujo en pacientes adultos con COVID-19, Hospital Universitario San Ignacio – Bogotá, D.C. 2020 a 2022

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.
Show authors biography
The COVID-19 pandemic made health personnel look for new and suitable uses for current devices to treat patients suffering from this pathology. High-flow nasal cannulas became a device that supported therapy against hypoxemia in patients with COVID-19, as has been demonstrated around the world in different pathologies.
The presentation of COVID-19 is that of a respiratory infection with symptoms ranging from a mild illness, similar to the common cold, to a severe, potentially fatal viral pneumonia (1). Although most people with SARS-CoV-2 have mild illness (81%), some will develop severe illness requiring oxygen therapy (14%) and others will require treatment in intensive care units and invasive mechanical ventilation (5% ). ). The most common diagnosis in patients with severe COVID-19 is severe pneumonia (2).
Considering the impact that this pathology has had on the world and the increased need for mechanical ventilation and its complications, it is necessary to know if the use of new therapies reduces the need for orotracheal intubation and the mortality of patients with COVID-19.
For this reason, we describe the experience at the San Ignacio University Hospital with the use of HFNC in adult patients with COVID-19 and the impact on the need for IOT and mortality.
This study presents a detailed analysis of 604 patients diagnosed with COVID-19 confirmed by RT-PCR or antigen at the time of admission, in whom the high-flow nasal cannula was used as a ventilatory support strategy, with the objective of identifying characteristics . clinical and prognostic factors associated with critical outcomes. Demographic variables, comorbidities, clinical and paraclinical parameters, as well as the relationship between the need for interventions such as high-flow nasal cannula with orotracheal intubation and mortality were examined.
Article visits 19 | PDF visits
Downloads
- Giwa AL, Desai A, Duca A. Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency clinicians. Emerg Med Pract. 2020;22(5):1–28. PMID: 32207910
- Cook TM, El-Boghdadly K, McGuire B, McNarry AF, Patel A, Higgs A. Consensus guidelines for managing the airway in patients with COVID-19: Guidelines from the Difficult Airway Society, the Association of Anaesthetists the Intensive Care Society, the Faculty of Intensive Care Medicine and the Royal College of Anaesthetist. Anaesthesia. 2020;1–15. doi: 10.1111/anae.15054. Epub 2020 Apr 1.
- Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451–60. doi: 10.1056/NEJMcp2009575. Epub 2020 May 15.
- Lodeserto FJ, Lettich TM, Rezaie SR. High-flow Nasal Cannula: Mechanisms of Action and Adult and Pediatric Indications. Cureus. 2018;10(11). doi: 10.7759/cureus.3639.
- Gershengorn HB, Hu Y, Chen JT, Hsieh SJ, Dong J, Gong MN, et al. The impact of high-flow nasal cannula use on patient mortality and the availability of mechanical ventilators in COVID-19. Ann Am Thorac Soc. 2021;18(4):623–31. doi: 10.1513/AnnalsATS.202007-803OC.
- Nishimura M. High-flow nasal cannula oxygen therapy devices. Respir Care. 2019;64(6):735–42. doi: 10.4187/respcare.06718.
- Nishimura M. High-flow nasal cannula oxygen therapy in adults. J Intensive Care. 2015;3(1):1–8. doi: 10.1186/s40560-015-0084-5. eCollection 2015.
- Mauri T, Wang YM, Corte FD, Corcione N, Spinelli E, Pesenti A. Nasal high flow: Physiology, efficacy and safety in the acute care setting, a narrative review. Open Access Emerg Med. 2019;11:109–20. doi: 10.2147/OAEM.S180197. eCollection 2019.
- Cook TM, El-Boghdadly K, McGuire B, McNarry AF, Patel A, Higgs A. Consensus guidelines for managing the airway in patients with COVID-19: Guidelines from the Difficult Airway Society, the Association of Anaesthetists the Intensive Care Society, the Faculty of Intensive Care Medicine and the Royal College of Anaesthetist. Anaesthesia. 2020;75(6):785–99. doi: 10.1111/anae.15054. Epub 2020 Apr 1.
- Agarwal A, Basmaji J, Muttalib F, Granton D, Chaudhuri D, Chetan D, et al. High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. Can J Anesth [Internet]. 2020;67(9):1217–48. Available from: https://doi.org/10.1007/s12630-020-01740-2
- Whittle JS, Pavlov I, Sacchetti AD, Atwood C, Rosenberg MS. Respiratory support for adult patients with COVID‐19. J Am Coll Emerg Physicians Open. 2020;1(2):95–101. doi: 10.1002/emp2.12071. eCollection 2020 Apr.
- Vianello A, Arcaro G, Molena B, Turato C, Sukthi A, Guarnieri G, et al. High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection. Thorax. 2020;75(11):998–1000. doi: 10.1136/thoraxjnl-2020-214993.
- Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. Ann Intensive Care. 2020;10(1):0–4. doi: 10.1186/s13613-020-00653-z.
- Frat J-P, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. N Engl J Med. 2015;372(23):2185–96. doi: 10.1056/NEJMoa1503326.
- Teng X bao, Shen Y, Han M feng, Yang G, Zha L, Shi J feng. The value of high-flow nasal cannula oxygen therapy in treating novel coronavirus pneumonia. Eur J Clin Invest. 2021;51(3):1–6. doi: 10.1111/eci.13435.
- Blez D, Soulier A, Bonnet F, Gayat E, Garnier M. Monitoring of high-flow nasal cannula for SARS-CoV-2 severe pneumonia: less is more, better look at respiratory rate. Intensive Care Med [Internet]. 2020;46(11):2094–5. Available from: https://doi.org/10.1007/s00134-020-06199-9
- Hu M, Zhou Q, Zheng R, Li X, Ling J, Chen Y, et al. Application of high-flow nasal cannula in hypoxemic patients with COVID-19: a retrospective cohort study. BMC Pulm Med [Internet]. 2020;20(1):1–7. Available from: https://doi.org/10.1186/s12890-020-01354-w
- Singh A, Khanna P, Sarkar S. High-Flow Nasal Cannula, a Boon or a Bane for COVID-19 Patients? An Evidence-Based Review. Curr Anesthesiol Rep. 2021; doi: 10.1007/s40140-021-00439-4
- Pérez-Nieto OR, Guerrero-Gutiérrez MA, Deloya-Tomas E, Ñamendys-Silva SA. Prone positioning combined with high-flow nasal cannula in severe noninfectious ARDS. Crit Care. 2020;24(1):10–2. https://doi.org/10.1186/s13054-020-2821-y
- Lu X, Xu S. Therapeutic effect of high-flow nasal cannula on severe COVID-19 patients in a makeshift intensive-care unit: A case report. Medicine (Baltimore). 2020;99(21):e20393. doi: 10.1097/MD.0000000000020393
- Calligaro GL, Lalla U, Audley G, Gina P, Miller MG, Mendelson M, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study: HFNO for COVID-19 pneumonia. EClinicalMedicine. 2020;000:1–9. doi: 10.1016/j.eclinm.2020.100570. Epub 2020 Oct 6.
- Patel M, Gangemi A, Marron R, Chowdhury J, Yousef I, Zheng M, et al. Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure. BMJ Open Respir Res. 2020;7(1):1–11. doi: 10.1136/bmjresp-2020-000650.
- Kharroubi SA, Diab-El-Harake M. Sex-differences in COVID-19 diagnosis, risk factors and disease comorbidities: A large US-based cohort study. Front Public Heal. 2022;10(March 2020). doi: 10.3389/fpubh.2022.1029190. eCollection 2022.
- Yau CE, Lee DYX, Vasudevan A, Goh KJ, Wong E, Ho AFW, et al. Performance of the ROX index in predicting high flow nasal cannula failure in COVID-19 patients: a systematic review and meta-analysis. Crit Care [Internet]. 2023;27(1):1–13. Available from: https://doi.org/10.1186/s13054-023-04567-7
- Mucha SR, Dugar S, McCrae K, Joseph DE, Bartholomew J, Sacha G, et al. Coagulopathy in COVID-19: Posted april 24, 2020. Cleve Clin J Med. 2020;87(5):461–8. Doi: 10.3949/ccjm. 87a.ccc024
- Giwa AL, Desai A, Duca A. Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency clinicians. Emerg Med Pract. 2020;22(5):1–28. PMID: 32286766.
- Swenson KE, Hardin CC. Pathophysiology of Hypoxemia in COVID-19 Lung Disease. 2020;(January). doi: 10.1016/j.ccm.2022.11.007. Epub 2022 Nov 23
- Yau CE, Lee DYX, Vasudevan A, Goh KJ, Wong E, Ho AFW, et al. Performance of the ROX index in predicting high flow nasal cannula failure in COVID-19 patients: a systematic review and meta-analysis. Crit Care [Internet]. 2023;27(1):1–13. Available from: https://doi.org/10.1186/s13054-023-04567-7
- Terzic CM, Medina-Inojosa BJ. Cardiovascular Complications of Coronavirus Disease-2019. Phys Med Rehabil Clin N Am [Internet]. 2023;34(3):551–61. Available from: https://doi.org/10.1016/j.pmr.2023.03.003
- Ospina-Tascón GA, Calderón-Tapia LE, García AF, Zarama V, Gómez-Álvarez F, Álvarez-Saa T, Pardo-Otálvaro S, Bautista-Rincón DF, Vargas MP, Aldana-Díaz JL, Marulanda Á, Gutiérrez A, Varón J, Gómez M, Ochoa ME, Escobar E, Umaña M, Díez J, Tobón GJ, Albornoz LL, Celemín Flórez CA, Ruiz GO, Cáceres EL, Reyes LF, Damiani LP, Cavalcanti AB; HiFLo-Covid Investigators. Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021 Dec 7;326(21):2161-2171. doi: 10.1001/jama.2021.20714. Erratum in: JAMA. 2022 Mar 15;327(11):1093. doi: 10.1001/jama.2022.1908.